Parkinson's

What Home DNA Tests Really Tell Us
What Home DNA Tests Really Tell Us23andMe recently gained FDA approval, but will it actually help keep people healthier?
Parkinson’s disease: Unmet needs to be fulfilled by novel therapies and reformulationsThe current global Parkinson’s disease market is characterized by a number of unmet needs, which include addressing the motor complications of dyskinesia and off-episodes. The recent approval of novel therapies and reformulations of existing drugs has the potential to fulfill some of these unmet needs, particularly in patients with advanced disease.
FDA approves generic Comtan tablets for Parkinson'sFDA has approved Aurobindo’s entacapone tablets USP, 200 mg, the generic equivalent to Novartis’ Comtan tablets 200 mg.
Study: Reduce long-term care use among patients with Parkinson’s disease psychosisReducing long-term care utilization among patients with Parkinson’s disease psychosis (PDP) may lower overall economic burden, according to data presented at the American Managed Care Pharmacy 27th Annual Meeting & Expo in San Diego.
FDA approves Rytary for Parkinson’s diseaseFDA approved an extended-release oral capsule formulation of carbidopa-levodopa (Rytary, Impax Pharmaceuticals, a division of Impax Laboratories, Inc.) for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication and / or manganese intoxication.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.
FDA drug approvals-July 2014FDA drug approvals, priority review, breakthrough designation, fast-track designations, orphan drug designations, first-time generic approval
Parkinson’s disease treatment can cause rare adverse eventDermatological side effects can occur with treatments for non-dermatological conditions, and consultation with a dermatologist may be a wise step in such cases.
Pipeline PreviewRecent FDA action (through January 2013) related to, IPX066, Afatinib, Enobosam, GTx-024, Elafin, Ezatiostat HCL, Tranexamic acid tablets, Lamotrigine extended-release tablets